Cell Cryopreservation Market Overview
The Cell Cryopreservation Market is expanding as cell and gene therapy development, biobanking, regenerative medicine, fertility preservation, and biological sample storage continue to advance. Growing demand for reliable cell preservation technologies, increasing investment in biopharmaceutical research, and the development of automated cryogenic storage systems are supporting market growth. The shift toward closed-system platforms, chemically defined media, and advanced cell-freezing technologies is also creating new opportunities across research and clinical applications.
According to the Market Research Future report updated August 24, 2026, the global Cell Cryopreservation Market was valued at USD 14.93 Billion in 2025 and is projected to grow from USD 17.89 Billion in 2026 to USD 90.92 Billion by 2035, registering a CAGR of 19.8% during 2026–2035. North America holds approximately 38% of global revenue, while Asia-Pacific is the fastest-growing region with a projected CAGR of more than 22%. Cryopreservation Media accounts for approximately 42% of market revenue, Equipment is the fastest-growing product segment at about 21.3% CAGR, and Stem Cells represent the largest application segment.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/21534
Key players driving innovation and competitiveness in the Cell Cryopreservation Market include:
Thermo Fisher Scientific
Merck KGaA
BioLife Solutions
Chart Industries
PHC Holdings
Azenta
Worthington Industries
Origen Biomedical
So-Low Environmental Equipment
The market is being shaped by the rapid expansion of cell and gene therapy pipelines, increasing biobank infrastructure, rising fertility preservation demand, and growing requirements for GMP-grade cryopreservation media. Pharmaceutical and biotechnology companies are increasingly investing in validated freezing, storage, monitoring, and transportation systems to maintain cell viability throughout complex supply chains. Automation, closed-system processing, and digital sample tracking are further improving the reliability of cryopreservation workflows.
The Cell Cryopreservation Market can be segmented by Type into Cell Freezing Media, Equipment, Consumables, and Others. By Application, it includes Stem Cells, Oocyte Cells, Sperm Cells, and Others. By End User, it covers Pharmaceutical and Biotechnology Companies, Research Institutes, Biobanks, IVF Clinics, and Others. By Region, it includes North America, Europe, Asia-Pacific, and the Rest of the World.
The growing need for reliable biological sample preservation is creating opportunities for cryopreservation equipment manufacturers, biotechnology companies, pharmaceutical organizations, biobanks, research institutions, IVF clinics, and specialized cold-chain providers. Automated controlled-rate freezers, xeno-free media, DMSO-free formulations, cryopreservation-as-a-service, AI-assisted freeze-thaw optimization, and integrated sample-management systems can support future market expansion.
Recent Developments and Market Trends:
Cryopreservation Media remains the largest product segment with approximately 42% share, supported by increasing demand for chemically defined and xeno-free formulations for clinical and research applications.
Equipment is the fastest-growing product category at approximately 21.3% CAGR as laboratories and biopharmaceutical manufacturers move from manual freezing systems toward automated controlled-rate freezers and monitored cryogenic storage platforms.
Stem Cells represent the leading application segment, with a 2025 market value of approximately USD 5.52 Billion, supported by cell and gene therapy development, regenerative medicine, and cord-blood banking.
Oocyte and embryonic cell preservation is expanding at approximately 20.8% CAGR as fertility preservation and assisted reproductive technologies increase demand for advanced vitrification and cell-freezing solutions.
Pharmaceutical and biotechnology companies represent a major end-user group because cell and gene therapy manufacturing requires validated cryopreservation at multiple points across the production and delivery chain.
Research institutes continue to generate demand for cryogenic storage equipment, consumables, and preservation media as stem-cell research, regenerative medicine, and biological studies expand.
IVF clinics are emerging as an important growth channel as fertility preservation and oocyte vitrification become more widely adopted.
Cell and gene therapy commercialization is one of the major growth drivers because cryopreservation is required at multiple supply-chain stages, including collection, manufacturing, transportation, and point-of-care delivery.
Government-supported biobank expansion programs are increasing investment in biological sample preservation infrastructure and creating additional demand for cryogenic storage systems.
The development of GMP-grade, chemically defined, and xeno-free cryopreservation media is gaining importance as manufacturers and healthcare organizations seek products suitable for clinical-grade cell processing.
DMSO-free and reduced-DMSO cryoprotectant formulations are gaining attention as companies seek alternatives to conventional cryoprotectants and aim to improve the tolerability of cell-based therapies.
AI-powered bioprocess optimization is creating opportunities to improve freeze-thaw protocols by analyzing cell-specific viability data and adjusting cooling parameters.
Cryopreservation-as-a-service models are emerging as third-party providers offer freezing, long-term storage, monitoring, and transportation services, reducing infrastructure requirements for smaller biotechnology companies.
Automated sample tracking using digital systems and RFID technologies is improving inventory management, traceability, and operational efficiency within large biobanks.
North America remains the leading regional market with approximately 38% share, supported by strong cell and gene therapy activity, biopharmaceutical manufacturing infrastructure, and investment in biobanking.
Europe holds approximately 27% of the global market, supported by biobank infrastructure, research funding, and regulatory development related to advanced therapies.
Asia-Pacific is the fastest-growing regional market, expanding at more than 22% CAGR, supported by increasing IVF activity, biobanking investments, healthcare infrastructure development, and expanding biotechnology capabilities.
High capital costs for automated cryogenic storage systems can remain a challenge, particularly for smaller research organizations and healthcare facilities in emerging markets.
DMSO toxicity concerns, cold-chain infrastructure gaps, limited skilled personnel, and the lack of harmonized international biobanking standards can also influence adoption across some regions.
Reasons to Buy the Report:
Provides comprehensive insights into the Cell Cryopreservation Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across cryopreservation media, equipment, consumables, and other preservation technologies.
Offers detailed segmentation analysis across type, application, end user, and geographic markets.
Includes competitive intelligence covering leading cryopreservation, biotechnology, pharmaceutical, biobanking, and laboratory-equipment companies.
Supports informed business decisions using market forecasts, cell and gene therapy trends, biobank expansion, fertility preservation, technological advancements, regulatory developments, and regional opportunities.
Future Outlook:
The future of the Cell Cryopreservation Market will be shaped by the expansion of cell and gene therapies, increasing biobanking activity, regenerative medicine research, fertility preservation, automation, and advances in cryoprotectant formulations. Cryopreservation Media should remain the leading product category, while Equipment is positioned for strong growth as automated controlled-rate freezing and monitored cryogenic storage systems gain adoption.
Stem Cells should continue to represent the largest application segment, while Oocyte and Embryonic Cells are expected to experience strong growth as fertility preservation and assisted reproductive services expand. Pharmaceutical and Biotechnology Companies should remain major end users, while IVF Clinics and Biobanks are expected to generate increasing demand for specialized preservation technologies.
North America should retain market leadership, while Asia-Pacific is expected to remain the fastest-growing region as biotechnology investment, IVF services, and biobanking infrastructure continue to develop. AI-assisted cryopreservation, DMSO-free media, automated sample management, cryopreservation-as-a-service, closed-system processing, and sustainable cryogenic technologies are expected to influence the next phase of market development.
Market Research Future projects the Cell Cryopreservation Market to reach USD 90.92 Billion by 2035 at a CAGR of 19.8%.
➤➤Explore Our Latest Related Reports:
